Home Newsfeeds Societe Generale Downgrades AbbVie to Hold

Societe Generale Downgrades AbbVie to Hold

Societe Generale analyst Justin Smith downgrades AbbVie (NYSE:ABBV) from Buy to Hold.

byBenzinga Newsdesk

November 8, 2022

1 minute read

Societe Generale analyst Justin Smith downgrades AbbVie (NYSE:ABBV) from Buy to Hold.

Who Is Going To Cash the Microsoft-Google AI Search Rivalry? Analyst Says Apple

By Anusuya Lahiri

April 18, 4:00 PM

BofA analyst Wamsi Mohan maintains a Neutral rating on Apple Inc (NASDAQ: AAPL) with a pr

AAPL

Gaucho Group Holdings, Inc. Announces 1-For-12 Reverse Stock Split

By Benzinga Newsdesk

November 3, 3:57 PM

Gaucho Group Holdings, Inc. (NASDAQ:VINO), a company that includes a growing collection of e-commerce platforms with a concentration on fine wines, luxury real estate, and leather goods and accessories (the

VINO

BitNile Holdings Issues November Bitcoin Production And Mining Operation Report

By Benzinga Newsdesk

December 1, 7:32 AM

BitNile Holdings, Inc. (NYSE:NILE), a diversified holding company ("BitNile" or the "Company") today published an unaudited update on Bitcoin production and miner installation. The number of

NILE

Larimar Therapeutics’ Friedreich’s Ataxia Investigational Drug Differentiated From Biogen’s Marketed Drug

By Vandana Singh

May 21, 2:39 PM

Larimar Therapeutics announces FDA lift of partial clinical hold on nomlabofusp (CTI-1601) for Friedreich's Ataxia. Data from Phase 2 study shows well-tolerated treatment with significant frataxin level increases.

BIIB

Societe Generale Downgrades AbbVie to Hold

Related Posts

Who Is Going To Cash the Microsoft-Google AI Search Rivalry? Analyst Says Apple

Gaucho Group Holdings, Inc. Announces 1-For-12 Reverse Stock Split

BitNile Holdings Issues November Bitcoin Production And Mining Operation Report

Larimar Therapeutics’ Friedreich’s Ataxia Investigational Drug Differentiated From Biogen’s Marketed Drug